ClinicalTrials.gg
RecruitingNCT06282133EC-II-Ado-PUpdated Feb 28, 2024

Behavioural Experiments for Generalized Anxiety in Adolescents - Pilot Study

An interventional study of Behavioural Experiments for Intolerance of Uncertainty in Generalized Anxiety Disorder and Adolescent - Emotional Problem, sponsored by Universite du Quebec en Outaouais. Recruiting at 1 site in Canada. Open to participants aged 14 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Universite du Quebec en Outaouais · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
14 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Generalized Anxiety Disorder with a site in Canada — 7 open to participants now, 11 under way, none of them phase 3. Generalized Anxiety Disorder · Canada.

Planned enrollment
39th of 45
8 · median 63
Started
2024
with 2 others
No phase
32 of 50
4 open now
Primary completion
2024-07
later than 1 of 10 live
Registered
46th of 50
by date
Lead sponsor
3 of 50
Universite du Quebec en Outaouais

Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, this one is the 39th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2024, is one of 32 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 46th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

7 of the 50 studies in Generalized Anxiety Disorder with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 14 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Generalized Anxiety Disorder with a site in Canada, or all of them as a file.
02

Study summary

Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry and anxiety. In adolescents, this condition can seriously impact their development, academic performance, and social relationships. In Canada, 3 to 4% of the population (between 0.9% and 2.7% among adolescents) suffers from GAD at any given time in their lives. These young individuals experience a reduced quality of life and are at risk for numerous medical conditions, as well as additional psychological issues. Research suggests that both pharmacological and psychological approaches are effective in treating GAD in the short term. However, psychological treatments appear to offer the greatest long-term benefits. There are a number of effective psychological treatments for GAD, most of which fall under cognitive-behavioural therapy (CBT) adapted for this age group.

In the 1990s, a group of Canadian researchers developed a CBT protocol for GAD that included four components. Data from six clinical trials in adults suggest that one of the four components is particularly important for treatment success: exposing oneself to uncertainty rather than avoiding it in daily life. In other words, learning to tolerate and manage uncertainty seems to be the key to reducing worry and anxiety.

Given this discovery, researchers developed a new treatment that exclusively targets intolerance to uncertainty and then adapted it for adolescents: Behavioural Experiments for Intolerance to Uncertainty in Adolescents (EC-IIA). The aim of the current pilot study is to test the effectiveness of EC-IIA in adolescent individuals. A total of 8 participants with a primary diagnosis of GAD will receive EC-IIA and will be evaluated at 4 different times ranging from pre-treatment to a 6-month follow-up. Conditions will be compared in terms of treatment efficacy and mechanisms. Researchers will also examine predictors of change during the 6 months following treatment. The proposed study will produce data on the effectiveness and mechanisms of a treatment for GAD that is less costly, less complex, and easier to disseminate than currently available treatments.

03

Conditions studied

  • Generalized Anxiety Disorder
  • Adolescent - Emotional Problem

Keywords

  • Cognitive-behavioural therapy
04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Adolescents aged between 14 and 18 years; 2) primary diagnosis of Generalized Anxiety Disorder (GAD); 3) no change in type or dose of medication in the 4 to 12 weeks preceding entry into the study (4 weeks for benzodiazepines, 12 weeks for antidepressants, hypnotics, and psychostimulants); 4) willingness to maintain stable medication status during participation in the study; 5) absence of consumption of herbal products known to have effects on the central nervous system in the 2 weeks preceding entry into the study; 6) absence of evidence of suicidal intent (based on clinical judgment); 7) absence of evidence of current substance use, current or past schizophrenia, bipolar disorder, or organic mental disorder; 8) absence of current participation in other clinical trials (i.e., psychotherapeutic services); 9) absence of concurrent psychotherapy during the trial treatment phase; 10) absence of evidence of anxiety symptoms due to a general medical condition based on clinical judgment (e.g., clinical hyperthyroidism, hypoglycemia, anemia).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Behavioural Experiments (CBT)

    Behavioural experiments involve selecting a specific thought to test (for example, "uncertainty makes me incapable of acting") and designing a detailed experiment to challenge this thought.

    Behavioral: Behavioural Experiments for Intolerance of Uncertainty

Interventions

  • BehavioralBehavioural Experiments for Intolerance of Uncertainty

    Behavioural experiments involve selecting a specific thought to test (for example, "uncertainty makes me incapable of acting") and designing a detailed experiment to challenge this thought.

    Also known as: CBT

06

What researchers measure

Primary outcomes

  1. Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5)

    Structured diagnostic interview

    Time frame: 10 weeks

Secondary outcomes

  1. Worry and Anxiety Questionnaire (WAQ)

    Self-report questionnaire

    Time frame: 10 weeks

  2. Penn State Worry Questionnaire (PSWQ)

    Self-report questionnaire

    Time frame: 10 weeks

  3. Beck Anxiety Inventory (BAI)

    Self-report questionnaire

    Time frame: 10 weeks

  4. Beck Depression Inventory-II (BDI-II)

    Self-report questionnaire

    Time frame: 10 weeks

Other outcomes

  1. Intolerance of Uncertainty Scale (IUS)

    Self-report questionnaire

    Time frame: 10 weeks

  2. Safety Behaviors Questionnaire (SBQ)

    Self-report questionnaire

    Time frame: 10 weeks

  3. Treatment Acceptance and Adherence Scale (TAAS)

    Self-report questionnaire

    Time frame: 3 weeks

  4. Working Alliance Inventory (WAI)

    Self-report questionnaire

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jul 2024, 5 months after the start.

Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 5 months is below that.

Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 28, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Jul 1, 2024
CompletionEst.
Jan 1, 2025
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06282133
Lead sponsor
Universite du Quebec en Outaouais
Responsible party
Michel Dugas, Ph.D. (Professor of Psychology, Universite du Quebec en Outaouais) — Principal investigator
First posted
Feb 28, 2024
Start date
Feb 1, 2024
Primary completion
Jul 1, 2024 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Feb 28, 2024

Study contacts

Sylvain C. Lemay, B.A. Psych
Contact
anxiete@uqo.ca
819-595-3900 ext. 2501
Michel J. Dugas, Ph.D.
Contact
michel.dugas@uqo.ca
819-595-3900 ext. 2509
Michel J. Dugas, Ph.D.
principal investigator · Universite du Quebec en Outaouais

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion